Pathophysiological Association of Alzheimer's Disease and Hypertension: A Clinical Concern for Elderly Population
Qianqian Yao,Kexin Jiang,Fei Lin,Tao Zhu,Nazeer Hussain Khan,Enshe Jiang
DOI: https://doi.org/10.2147/cia.s400527
IF: 3.829
2023-05-05
Clinical Interventions in Aging
Abstract:Qianqian Yao, 1, &ast Kexin Jiang, 1, &ast Fei Lin, 2 Tao Zhu, 3 Nazeer Hussain Khan, 1, 4 Enshe Jiang 1, 4 1 Institute of Nursing and Health, Henan University, Kaifeng, People's Republic of China; 2 School of Medicine, Shangqiu Institute of Technology, Shangqiu, People's Republic of China; 3 Department of Geriatrics, Kaifeng Traditional Chinese Medicine Hospital, Kaifeng, People's Republic of China; 4 Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, People's Republic of China &astThese authors contributed equally to this work Correspondence: Enshe Jiang, Email Alzheimer's disease (AD), the most common cause of dementia and the fifth leading cause of death in the adult population has a complex pathophysiological link with hypertension (HTN). A growing volume of published literature on a parallel elevation of blood pressure (BP), amyloid plaques, and neurofibrillary tangles formation in post-middle of human brain cells has developed new, widely accepting foundations on this association. In particular, HTN in elderly life mediates cerebral blood flow dysfunction, neuronal dysfunction, and significant decline in cognitive impairment, primarily in the late-life populace, governing the onset of AD. Thus, HTN is an established risk factor for AD. Considering the impact of AD, 1.89 million deaths annually, and the failure of palliative therapies to cure AD, the scientific research community is looking to adopt integrated approaches to target early modified risk factors like HTN to reduce AD burden. The current review highlights the significance and impact of HTN-based prevention in lowering the AD burden in the elderly by providing a comprehensive overview of the physiological relationship between AD and HTN with an in-detail explanation of the role and applications of pathological biomarkers in this clinical association. The review will gain worth in presenting new insights and providing inclusive discussion on the correlation between HTN and cognitive impairment. It will increase across a wider scientific audience to expand understanding of this pathophysiological association. Keywords: Alzheimer's disease, hypertension, elderly population, clinical biomarkers Alzheimer's disease (AD) is one of the leading age-related brain diseases in older adults and imposes a high impact. There are more than 1.89 million deaths annually, with estimated healthcare costs of $305 billion. 1,2 The high prevalence of this chronic age-related disease is raising clinical concerns in the elderly population. For example, 6.5 million Americans over 65 lived with AD and other dementia-related illnesses, which caused 121,499 deaths in 2019. 3 Unfortunately, this disease has no definitive cure, and the available drugs only relieve the patients from symptoms. 4 This lack of specific treatment and the failure of available palliative therapies for AD have increased the mortality rate among older people, especially in low-income countries. 5 In addition, clinically, there is no obvious mechanism for mid-life AD development. Despite the many physio-clinical strides made in the past two decades, there is still enough to investigate responsible factors and their mechanism of action in AD development. 6 For most of history, researchers have classified the driving forces in the onset of AD pathology into two main groups: non-modifiable risk factors (aging, sex and genetics) and modifiable risk factors. 7,8 In addition, the educational-learning level, smoking, high body weight, diabetes, and hypertension (HTN) are interlinked with the pathology of the disease. 9 It has been observed that intervention of modifiable risk factors could prevent the up to 35% of AD-related dementia cases. 10 In addition, positive lifestyle changes like diet and exercise can prevent cognitive functioning deterioration. 11 With some limitations, many studies have concluded that strategic preclinical intervention may prevent the onset and development of AD if the risk factor is the cause and slow down the progression of the disease if the risk factor is a symptom. 12,13 In particular, HTN is the most decisive factor in all modifiable risk factors mediating AD development. 14,15 Targeting HTN has a considerable impact on lowering AD in the elderly population. Figure 1 explains the modifiable risk factors-treatable medical conditions and lifestyle choices that play a role in AD onset. Figure 1 Figurative description of a modified risk factor for AD developments. Today's population aged 65 and over is expected to grow rapidly, and older -Abstract Truncated-
geriatrics & gerontology,gerontology